Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis

Acta Haematologica

Volumn 114, Issue 1, 2005, Pages 26-40

  Butterfield, J H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Corticosteroids; Granulocyte macrophage colony stimulating factor; Hypereosinophilic syndrome; Interferon 2A; Interferon 2B; Interferon ; Interleukin 13; Interleukin 5; Systemic mastocytosis; T cells; Tryptase

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HYDROXYUREA; LORATADINE; MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

AUTOIMMUNE DISEASE; BONE DENSITY; BONE MARROW; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME ABERRATION; COLONY FORMATION; DELUSION; DEPRESSION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EOSINOPENIA; EOSINOPHIL; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HASHIMOTO DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; MAST CELL; MAST CELL LEUKEMIA; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCHOSIS; REVIEW; SKIN DEFECT; SKIN DISEASE; SKIN NODULE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPREGULATION; URTICARIA; VERTEBRA FRACTURE; VISUAL HALLUCINATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EOSINOPHILS; HUMANS; HYDROXYUREA; HYPEREOSINOPHILIC SYNDROME; INTERFERON ALFA-2A; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MYELOPOIESIS; PREDNISONE; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON;

EID: 21344466047     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085560     Document Type: Review

References (139)

1. Hardy WR, Anderson RE: The hypereosinophilic syndromes. Ann Intern Med 1968;68: 1220-1229.
2. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine 1975;54:1-27.
3. Bain BJ: Hypereosinophilia. Curr Opin Hematol 2000;7:21-25.
4. Brito-Babapulle F: Review. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003;121:203-223.
5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG: A tyrosine kinase created by fusion of the PDGFRA and FiP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
6. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB: Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101: 4660-4666.
7. Kitano K, Ichikawa N, Mahbub D, Ueno M, Ito T, Shimodaira S, Kodaira H, Ishida F, Kobayashi H, Saito H, Okubo Y, Enokihara H, Kiyosawa K: Eosinophilia associated with proliferation of CD(3+)4-(8+) αβ+ T cells with chromosome 16 anomalies. Br J Haematol 1996;92:315-317.
8. - T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-1082.
9. Simon HU, Plotz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-1120.
10. Ogata M, Ogata Y, Kohno K, Uno N, Ohno E, Ohtsuka E, Saburi Y, Kamberi P, Nasu M, Kikuchi H: Eosinophilia associated with adult T-cell leukemia: Role of interleukin 5 and granulocyte-macrophage colony-stimulating factor. Am J Hematol 1998;59:242-245.
11. Murphy PT, Fenelly DF, Stuart M, O'Donnell JR: Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990;75:619-620.
12. Zielinski RM, Lawrence WD: Interferon-α for the hypereosinophilic syndrome. Ann Intern Med 1990;113:716-718.
13. Fruehauf S, Fiehn C, Haas R, Doehner H, Hunstein W: Sustained remission of idiopathic hypereosinophilic syndrome following α-interferon therapy. Acta Haematol 1993;89:91-93.
14. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H: Clinical and cytogenetic remission induced by interferon-α in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998;58:137-141.
15. Ceretelli S, Capochiani E, Petrini M: Interferon-α in the idiopathic hypereosinophilic syndrome: Consideration of five cases. Ann Hematol 1998;77:161-164.
16. Yoon T-Y, Ahn G-B, Chang S-H: Complete remission of hypereosinophilic syndrome after interferon-α therapy: Report of a case and literature review. J Dermatol 2000;27:110-115.
17. Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H, Shimada T, Nishwake K, Sakai O: Interferon-α therapy for the myeloproliferative variants of hypereosinophilic syndrome. Rinsho Ketseuki 1993; 34: 367-372.
18. Bockenstedt PL, Santinga JT, Bolling SF: α-Interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994; 45:248-251.
19. Acaba L, Mangual A, Garcia EV: Excellent response to interferon therapy in a patient with hypereosinophilic syndrome and elevated serum immunoglobulin E levels. Bol Assoc Med PR 2000;92:59-62.
20. Baratta L, Afeltra A, Delfino M, DeCastro S, Giorgino F, Rossi-Fanelli F: Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy. Case report and literature review. Angiology 2002;53:465-470.
21. Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B: Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(3; 7) aberration. Ann Hematol 2000;79:95-98.
22. Hansen PB, Johnsen HE, Hippe E: Hypereosinophilic syndrome treated with α-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity. Am J Hematol 1993;43:L66-L68.
23. Butterfield JH, Gleich GJ: Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121:648-653.
24. Busch FW, Schmidt H, Steinke B: Alpha-interferon for the hypereosinophilic syndrome. Ann Intern Med 1991;114:338-339.
25. Bletry O, Papo T: Les interferons. Interferons alpha et gamma: Indications dans les maladies systemiques. Ann Med Interne 1993;144:557-562.
26. Coutant G, Bletry O, Prin L, Hauteville D, De Puyfontaine O, Abgrall J-F, Godeau P: Traitement des syndromes hypereosinophiliques a expression myeloproliferative par l'association hydroxyuree-interferon alpha. Ann Med Intern 1993;144:243-250.
27. Esteve K, Cervantes F, Bosch F, Cobo F, Ciril Rozman EM: Tratamiento con interferon alfa del sindrome hipereosinofilico idiopatico resistente a la terapeutica convencional. Med Clin (Barc) 1996;106:30-32.
28. Demiroglu H, Dundar S: Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 1997;97:928-930.
29. Sato H, Danbara M, Tamura M, Morita M: Eosinophilic leukemia with a t(2;5)(p23;q35) translocation. Br J Haematol 1994;87:404-406.
30. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983;131:1300-1305.
31. Kioke T, Nakamura Y, Enokihara H: Interferon-α inhibits interleukin-5 and granulocyte-macrophage colony stimulating factor production by lymphocytes and suppresses eosinophil colony formation from bone marrow progenitor cells. Dokkyo J Med Sci 1998;25:45-52.
32. Desreumaux P, Janin A, Dubucquoi S, Copin MC, Torpier G, Capron A, Capro M, Prin L: Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Blood 1993;82:1553-1560.
33. Aldebert D, Lamkhioued B, Desaint C, Gounni AS, Goldman M, Capron A, Prin L, Capron M: Eosinophils express a functional receptor for interferon α: Inhibitory role of interferon α on the release of mediators. Blood 1996;87: 2354-2360.
34. + T cells. Blood 1997;89:1110-1111.
35. Ochiai K, Iwamoto I, Takahashi H, Yoshida S, Tomioka H, Yoshifda S: Effect of IL-4 and interferon-gamma (IFN-gamma) on IL-3 and IL-5-induced eosinophil differentiation from human cord blood mononuclear cells. Clin Exp Immunol 1995;99:124.
36. + T cells. J Exp Med 1993;177:573.
37. Valerius T, Repp R, Kalden JR, Platzer E: Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990;145:2950-2958.
38. Morita M, Lamkhioued B, Gounni AS, Aldebert D, Delaprte E, Capron A, Capron M: Induction by interferons of human eosinophil apoptosis and regulation by interleukin-3, granulocyte/macrophage-colony stimulating factor and interleukin-5. Eur Cytokine Netw 1996;7:725-732.
39. Nakajuma T, Yamashita N, Matsui H, Suzuki N, Kaneoka H, Mizuskima Y, Sakane T: Induction of differentiation into monocyte/macrophage cell lineage of a human eosinophilic leukaemia cell line EoL-1 by simultaneous stimulation with tumor necrosis factor-α and interferon-γ. Br J Haematol 1995;89:258-265.
40. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994;76:241-251.
41. Gutterman JU: Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci USA 1994;91:1198-1205.
42. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni M-P, Macchia D, Maggi E, Del Prete D, Romagnani S: IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992;149:2977-2983.
43. Milewski M, Libura M, Undas A, Rys D, Musial J, Szczeklik A: Interferon gamma abolishes aspirin-induced bronchoconstriction in a hypereosinophilic non-atopic patient. Eur Resp J 1995;8(suppl 19):432S abstract 2125.
44. Krishnaswamy G, Smith JK, Srikanth S, Chi DS, Kalbfleisch JH, Huang S-K: Lymphoblastoid interferon-α inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996;16:819-827.
45. Enokihara H, Nakamura Y, Nagashima S, Furusawa S, Shishido H: Regulation of interleukin-5 production by interleukin-4, interferon-alpha, transforming growth factor β and interleukin-6. Int Arch Allergy Immunol 1994; 104:44-45.
46. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP: IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799-803.
47. Resnick MB, Weller PF: Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 1993;8:349-355.
48. Krishnaswamy G, Hall K, Youngberg G, Hossler F, Johnson D, Block WA, Huang S-K, Kelley J, Chi DS: Regulation of eosinophil-active cytokine production from human cord blood-derived mast cells. J Interferon Cytokine Res 2002;22:379-388.
49. Raghavachar A, Fleischer S, Frickhofen N, Heimpel H, Fleischer B: T lymphocyte control of human eosinophil granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987;139:3753-3758.
50. + T cells. J Clin Invest 1996;97: 309-315.
51. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330:535.
52. Schandene L, Roufosse F, de Lavarfeille A, Stordeur P, Efira A, Kennes B, Cogan E, Goldman M: Interferon α prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96: 4285-4292.
53. Prin L, Plumas J, Gruart V, Loiseau S, Aldebert D, Ameisen JC, Vermersch A, Fenaux P, Bletry O, Capron M: Elevated serum levels of soluble interleukin-2 receptor: A marker of disease activity in the hypereosinophilic syndrome. Blood 1991;78:2626-2632.
54. Canonica GW, Passalacqua G, Pronzato C, Corbetta L, Bagnasco M: Effective long-term α-interferon treatment for hypereosinophilic syndrome. J Allergy Clin Immunol 1995;96: 131-155.
55. Granjo E, Lima M, Lopes JM, Doria S, Orfao A, Ying S, Barata LT, Cross NCP, Bain BJ: Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: Clinical, immunological and cytogenetic features and therapeutic approach. Acta Haematol 2002;107:108-112.
56. Schofield JR, Robinson WA, Murphy JR, Rovira DK: Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994;121:736-744.
57. Dicato M, Ries F, Duhem C: Long lasting remission of hypereosinophilic syndrome (HES) after alpha-interferon (IFN) treatment. Blood 1994;84(suppl 1):631a.
58. Malbrain MLNG, van den Bergh H, Zachee P: Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996;92:176-183.
59. Luciano L, Catalano L, Sarrantonio C, Guerriero A, Califano C, Rotoli B: αIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999;84:651-653.
60. van den Anker-Lugtenburg PJ, van't Veer MB: Alpha-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1991;77:258.
61. Wataabe K, Tournilhad O, Camilleri LF: Recurrent thrombosis of prosthetic mitral valve in idiopathic hypereosinophilic syndrome. J Heart Valve Dis 2002;11:447-449.
62. Leiferman KM, O'Duffy JD, Perrry HO, Greipp PR, Giuliani ER, Gleich GJ: Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA 1982;247:1018-1020.
63. Barouky R, Bencharif L, Badet F, Salles G, Durand DV, Rousset H: Mucosal ulcerations revealing primitive hypereosinophilic syndrome. Eur J Dermatol 2003;13:207-208.
64. DeYampert NM, Beck LA: Eosinophilia and multiple erythematous indurated plaques. Arch Dermatol 1997;133:1579-1584.
65. Mohr C, Schutte B, Hildebrand A, Luger TA, Kolde G: Eosinophilic pustular folliculitis: Successful treatment with interferon-alpha. Dermatology 1995;191:257-259.
66. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995;122:254-261.
67. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L: α-Interferon and hypereosinophilic syndrome with trisomy 8: Karyotypic remission. Blood 1995;85:2284-2285.
68. Tatsis E, Schnabel A, Gross WL: Interferon-α treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129: 370-374.
69. Valle MT, Figari O, Manca F, Damasio E: Three cases of hypereosinophilic syndrome (HES) and one case of Churg-Straus syndrome (CSS) treated with recombinant alpha interferon (α-IFN). Blood 1999;94(suppl 1):291b.
70. Lesens O, Hansmann Y, Nerson J, Pasquali J-L, Gasser B, Wihlm H-M, Christmann D: Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur J Intern Med 2002;13:458-462.
71. French LE, Shapiro M, Junkins-Hopkins JM, Wolfe JT, Rook AH: Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: Increased production of interleukin 5 and inhibition by interferon alfa. J Am Acad Dermatol 2003;49: 1170-1174.
72. Vilcek J, Feldman M: The sequences of IFN-alfa-2a and IFN-alfa-2b differ by one amino acid. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004;25:201-209.
73. Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 1987;56:727-777.
74. Kung TT, Stelts DM, Zurcher JA, Jones H, Umland SP, Egan RW, Kreutner W, Chapman RW: Interferon-γ and antibodies to interleukin-5 and interleukin-4 inhibit the pulmonary eosinophilia in allergic mice. Inflamm Res 1005;44(suppl 2):S185-S186.
75. Gisslinger H, Eichinger S, Gilly B, Weissel M, Lorber Ch, Lechner K: Exacerbation of autoimmunity during therapy with recombinant interferon alpha for hematological disorders. Ann Hematol 1992;65(suppl):A8.
76. Nassar GM, Pedro P, Remmers RE, Mohanty LB, Smith W: Reversible renal failure in a patient with the hypereosinophilic syndrome during therapy with alpha interferon. Am J Kidney Dis 1998;31:121-126.
77. Hendrick A: Case Report. Psychosis during interferon in eosinophilic leukaemia. Clin Lab Haematol 1994;16:295-296.
78. Kook H, Cho D, Noh H-Y, Kim S-Y, Hwang T-J: Chronic eosinophilic leukemia with uniquechromosomalabnormality,add(8)(p23), in a 14-month girl: Treatment with imatinib mesylate. Blood 2002;100:4931a.
79. Kanthawatana S, Irani AM, Schwartz LB: Recombinant interferon-alpha (IFNα) and pregnancy in a patient with hypereosinophilic syndrome. J Allergy Clin Immunol 1998;101:S20 (abstr 88).
80. Blanquer A, Lopez A, Tarin F, Hernandez F, Linares M: Alpha interferon for hypereosinophilic syndrome. Am J Hematol 1994;47:332-333.
81. George BO, Abdelaal MA, Gang MT, Kinsara AJ: Idiopathic hypereosinophilic syndrome: A report of four cases in Arabs, and a review of the literature. Afr J Med Sci 2001;30:241-249.
82. Papo T, Piette J-C. Hermine O: Treatment of the hypereosinophilic syndrome with interferon-α. Ann Intern Med 1995;123:155-156.
83. Chockalingam A, Jalil A, Shadduck RK, Lister J: Case Report. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 1999;23:1093-1094.
84. Xicoy B, Batlle M, Grau J, Ribera J-M, Gelpi H, Cuadras P: Transient demyelinating neurologic lesions in a patient with idiopathic hypereosinophilic syndrome. Am J Hematol 2002;69:153-154.
85. Juneja S, Stewart J, Mckenzie A, Venter D, Januszewicz H: Case report. Hypereosinophilic syndrome or chronic eosinophilic leukemia: Report of a case with a lytic bone lesion. Leukemia 1997;11:765-774.
86. Schwartz LB, Austen KF: Structure and function of the chemical mediators of mast cells. Prog Allergy 1984;34:271-321.
87. Wodnar-Fillpowicz A, Heusser CH, Moroni C: Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989;339:150-152.
88. Selvan RS, Butterfield JH, Krangel MS: Expression of multiple chemokine genes by a human mast cell leukemia. J Biol Chem 1994; 269:13893-13898.
89. Hamrin B: Release of histamine in urticaria pigmentosa. Lancet 1957;272:867-868.
90. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982;129: 1627-1631.
91. Valent P, Akin C, Sperr WR, Horny H-P, Arock M, Lechner K, Bennett JM, Metcalfe DD: Review. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol 2003;122:695-717.
92. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG: Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988;67:345-368.
93. Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001;25:603-625.
94. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny H-P, Bennett JM, Metcalfe DD: Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk Res 2003;27:635-641.
95. Galli SJ: Biology of disease: New insights into 'the riddle of the mast cells': Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5-33.
96. Fodinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, Valent P, Mannhalter C: Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994;84:2954-2959.
97. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-10564.
98. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behaviour. J Invest Dermatol 1998;111:1227-1231.
99. Bergmann L, Mitrou PS: Recombinant gamma interferon in the treatment of a patient with malignant mastocytosis. Blut 1985;51: 218.
100. Griesinger F, Bergmann L, Mitrou PS, Hoelzer D: Interferons in the treatment of malignant mastocytosis (MM) and CMMoL developing in MM (abstract). Blut 1987;55:309.
101. Fiehn C, Prummer O, Gallati H, Heilig B, Hunstein W: Treatment of systemic mastocytosis with interferon-γ: Failure after appearance of anti-IFN-γ antibodies. Eur J Clin Invest 1995;25:615-618.
102. Jaffe HS, Chen AB, Kramer S, Sherwin SA: Short communication. The absence of interferon antibody formation in patients receiving recombinant human interferon-gamma. J Biol Response Mod 1987;6:576-580.
103. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M: Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol 1991;85:220.
104. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, Willemze R: Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-623.
105. Butterfield JH: Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998;138:489-495.
106. Czarnetzki BM, Algermissen B, Jeep S, Haas N, Nurnberg W, Muller K, Kropp J-D: Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994;30:500-501.
107. Pfluger KH, Weide R, Ehlenz K, Lorenz W: Interferon alfa improves systemic mastocytosis and disease related osteoporosis. Ann Hematol 1993;67(suppl):A95.
108. Petit A, Pulik M, Gaulier A, Lionnet F, Mahe A, Sigal M: Systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical features and response to interferon alfa therapy. J Am Acad Dermatol 1995;32: 850-853.
109. Kolde G, Sunderkotter C, Luger TA: Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol 1995;133:91-94.
110. Butterfield JH, Tefferi A, Kozuh GF: Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case. Leuk Res 2005;29:131-134.
111. Symeonidis A, Kouraklis-Symenidis A, Melachrinou M, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Aoumbos N: Systemic mastocytosis associated with multiple sclerosis. The first case report. Blood 2004;96:269b.
112. Chosidow O, Becherel P-A, Piette J-C, Arock M, Debre P, Frances C: Tripe palms associated with systemic mastocytosis: The role of transforming growth factor-α and efficacy of interferon-alfa. Br J Dermatol 1998;138: 698-703.
113. Hubner C, Wedding U, Strater J, Limberg B, Stremmel W: Clinical stable systemic mastocytosis with interferon alpha-2b therapy. J Intern Med 1997;241:529-533.
114. Takasaki Y, Tsukasaki K, Jubashi T, Tomonaga M, Kamihira S, Makiyama K: Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-α. Intern Med 1998;37:484-488.
115. Reinacher-Schick A, Petrasch S, Longley BJ, Teschendorf C, Graeven U, Schmiegel W: Case report. C-kit mutation and osteopetrosis-like osteopathy in a patient with systemic mast cell disease. Ann Hematol 1998;77: 131-134.
116. Caksen H, Odabas D, Oner AF, Cesur Y, Arslan S, Akbayram S, Yuca SA, Erol M: Patient Report. Use of interferon alpha-2b and prednisolone in the treatment of severe intractable diarrhea in a child with systemic mastocytosis. Pediatr Int 2003;45:751-754.
117. Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphael M, Guillevin L, Lortholary O: Treatment of adult systemic mastocytosis with interferon-α: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-1097.
118. Fain O, Sitbon M, Sibony M, Frilay Y, Mathieu E, Lejeune F, Thomas M: Efficacite de l'interferon alpha dans un cas de mastocytose systemique. Ann Med Interne 1995;146:205-206.
119. Kirshenbaum AS, Worobec AS, Davis TA, Goff JP, Semere T, Metcalfe DD: Inhibition of human mast cell growth and differentiation by interferon gamma-1b. Exp Hematol 1998;26:245-251.
120. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD: Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996;22:501-505.
121. Schernthaner GH, Spanblochl E, Sperr WR, Sillaber C, Semper H, Jurecka W, Hagen W, Wolff K, Chott A, Lechner K, Valent P: Effects of α-interferon 2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis. Ann Hematol 2000;79:660-666.
122. Giraldo P, Arroyo A, Roca M, Garcia-Erce JA, Marin-Cardenas JA, Mayayo P, Rubio-Felix D, Giralt M: Evaluation of bone marrow pattern by magnetic resonance imaging in patients with systemic mastocytosis on therapy with α-interferon (abstract). Br J Haematol 1998;102:312.
123. Delaporte E, Pierard E, Wolthers BG, Desreumaux P, Janin A, Cortot A, Piette F, Bergoend H: Interferon-α in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479-482.
124. Bitar RI, Wisch N, Bozkowska B, Kafko M, Najfeld V: Interphase FISH unmasked aneuploidy of chromosomes 7, 8, X, and Y in cytogenetically normal patient with mast cell leukemia: The effect of alfa-interferon treatment. Blood 1997;(suppl 1):209.
125. Potter MN, Kennedy CTC, Mott MJ, Sainsbury C, Berry PJ: Congenital systemic mastocytosis. Br J Dermatol 1990;123(suppl 37): 70-74.
126. Schmidt M, Dercken C, Loke O, Reimann S, Diederich S, Blasius S, Heidenreich S: Case study. Pulmonary manifestation of systemic mast cell disease. Eur Respir J 2000;15:623-625.
127. McMullin MF, Chapple M, Vulliamy T, Adams J, Gordon A, Swirsky DM, Barrett AJ, Thorpe PA, Hughes RG: Systemic mastocytosis with an abnormally expanded T-cell clone. Leuk Lymphoma 1992;6:419-422.
128. Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah AJ, Dahinden C, Gerber NJ: Case report. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B. Br J Rheumatol 1996;35:898-900.
129. Lehmann T, Lammle B: IFN-α treatment in systemic mastocytosis. Ann Hematol 1999; 78:483-484.
130. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH: Case report. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:41-43.
131. Granerus G, Lonnqvist B, Roupe G: Histamine metabolism in mastocytosis patients treated with interferon α-2b. Inflamm Res 1996;45(suppl 1):S41-S43.
132. Irani AA, Nilsson G, Ashman LK, Schwartz LB: Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 1995;84:72-78.
133. Finotto S, Mekori YA, Metcalfe DD: Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells. J Clin Invest 1997;99:1721-1728.
134. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P: Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004;28: 249-257.
135. Jost E, Michaux L, Vanden Abeele M, Boland B, Latinne D, Godfraind C, Scheiff JM, Vaerman JL, Lecouvet F, Ferrant A: Case Report. Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage. Ann Hematol 2001; 80:302-307.
136. Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H, Parwaresch R: Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol 2001; 23:134-138.
137. Inaoui R, Petit B, Jaccard A, Bertin P, Treves R: Case report. Aggressive systemic mastocytosis. Joint Bone Spine 2003;70:64-66.
138. Harrison BD, Ashford RA, Hatton CSR: Case Report. Systemic mastocytosis - A case treated with interferon α and radiotherapy. Clin Lab Haematol 1994;16:291-294.
139. Prummer O: Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2a in an adjuvant multicenter trial. Cancer 1993;71: 1828-1834.